pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Dermatology · news · pharmadog
← back to Dermatology
News · Dermatology
112
stories
1d
STAT+: How health systems are embracing chatbots to query and summarize patient records
stat
1d
FDA Authorizes First-Of-Its-Kind Robotic Blood Draw Device
fda press
1d
Kolon TissueGene cuts 37 US staffers after Phase 3 fail
biospace
1d
11 companies hiring in New Jersey
biospace
2d
Merck, Moderna’s personalized cancer vaccine slows recurrence in phase 3, setting up approval push
fiercebiotech
2d
Leo Pharma buys rare skin disease drug in $435M deal
biopharma dive
2d
LEO adds to dermatology portfolio with $435M deal for late-stage rare disease drug
biospace
3d
Leo Pharma to license Tanabe’s rare disease drug for pain with sun exposure
endpoints
3d
Argenx jumps on Phase 3 data for blockbuster Vyvgart
biopharma dive
4d
Leo ‘really strengthening’ pipeline with $435M deal for Tanabe rare skin disease drug awaiting FDA nod
fiercebiotech
8d
Silence cashes in on ‘differentiated’ data; UK reaffirms support for childhood vaccines
biopharma dive
9d
Opinion: Climate change is making people with chronic illness even sicker
stat
9d
Chasing Dupixent, a biotech aims to make better antibody drugs for eczema
biopharma dive
9d
Vaderis hauls in $152M to test an AKT-targeting drug
biopharma dive
10d
‘We are proud to be in the lead’: Vaderis lands $152M for phase 3 study in rare blood vessel disorder
fiercebiotech
10d
MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial
fiercebiotech
11d
Labcorp nabs FDA green light for BRAF melanoma diagnostic
fiercebiotech
11d
Sobi pens $580M deal for Innate’s skin cancer drug ahead of phase 3 push
fiercebiotech
14d
Opinion: AI won’t enhance physician autonomy. It will further diminish it
stat
14d
FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Advanced Melanoma
fda press
14d
Alkeus, an unorthodox eye drug startup, acquired by Tarsus for up to $800M
biopharma dive
15d
Attovia adds to biotech IPO momentum with $289M offering
biopharma dive
15d
Sanofi suspends chronic lung disease phase 2 study, tied to ‘strategic business reasons’
fiercebiotech
16d
Attovia's CEO aims to scratch itch opportunity and challenge Dupixent with $289M IPO
fiercebiotech
16d
Merck’s $10.8B Prometheus deal delivers another win—plus a Phase 2b miss
biospace
16d
J&J pharma leader to retire; Krystal slumps on gene therapy miss
biopharma dive
16d
Smith & Nephew cuts 2026 outlook as US knee implant sales slide
fiercebiotech
16d
Merck's anti-TL1A antibody scores a win in hidradenitis suppurativa, fails in SSc-ILD
endpoints
18d
Recon: AstraZeneca, BMS discuss merger; FDA broadens indication for Novartis’ Pluvicto
raps
18d
Expert sees shift to ‘ecosystem-centric assurance’ under FDA’s distributed manufacturing rule
raps
← prev
page 1 of 4
next →
